Literature DB >> 19154427

Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel.

J Wu1, W-G Ding, H Matsuura, K Tsuji, W-J Zang, M Horie.   

Abstract

BACKGROUND AND
PURPOSE: Kv1.5 channels conduct the ultra-rapid delayed rectifier potassium current (I(Kur)), and in humans, Kv1.5 channels are highly expressed in cardiac atria but are scarce in ventricles. Pharmacological blockade of human Kv1.5 (hKv1.5) has been regarded as effective for prevention and treatment of re-entry-based atrial tachyarrhythmias. Here we examined blockade of hKv1.5 channels by LY294002, a well-known inhibitor of phosphatidylinositol 3-kinase (PI3K). EXPERIMENTAL APPROACH: hKv1.5 channels were heterologously expressed in Chinese hamster ovary cells. Effects of LY294002 on wild-type and mutant (T462C, H463C, T480A, R487V, A501V, I502A, I508A, L510A and V516A) hKv1.5 channels were examined by using the whole-cell patch-clamp method. KEY
RESULTS: LY294002 rapidly and reversibly inhibited hKv1.5 current in a concentration-dependent manner (IC(50) of 7.9 micromol.L(-1)). In contrast, wortmannin, a structurally distinct inhibitor of PI3K, had little inhibitory effect on hKv1.5 current. LY294002 block of hKv1.5 current developed with time during depolarizing voltage-clamp steps, and this blockade was also voltage-dependent with a steep increase over the voltage range for channel openings. The apparent binding (k(+1)) and unbinding (k(-1)) rate constants were calculated to be 1.6 micromol.L(-1) (-1).s(-1) and 5.7 s(-1) respectively. Inhibition by LY294002 was significantly reduced in several hKv1.5 mutant channels: T480A, R487V, I502A, I508A, L510A and V516A. CONCLUSIONS AND IMPLICATIONS: LY294002 acts directly on hKv1.5 currents as an open channel blocker, independently of its effects on PI3K activity. Amino acid residues located in the pore region (Thr480, Arg487) and the S6 segment (Ile502, Ile508, Leu510, Val516) appear to constitute potential binding sites for LY294002.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19154427      PMCID: PMC2697827          DOI: 10.1111/j.1476-5381.2008.00017.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

Review 1.  Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity.

Authors:  S Nattel; L Yue; Z Wang
Journal:  Cell Physiol Biochem       Date:  1999

2.  The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism.

Authors:  Wasim El-Kholy; Patrick E Macdonald; Jia-Hui Lin; Jing Wang; Jocelyn Manning Fox; Peter E Light; Qinghua Wang; Robert G Tsushima; Michael B Wheeler
Journal:  FASEB J       Date:  2003-02-05       Impact factor: 5.191

3.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

4.  IGF-1 up-regulates K+ channels via PI3-kinase, PDK1 and SGK1.

Authors:  N Gamper; S Fillon; S M Huber; Y Feng; T Kobayashi; P Cohen; F Lang
Journal:  Pflugers Arch       Date:  2001-11-14       Impact factor: 3.657

5.  Direct block by bisindolylmaleimide of rat Kv1.5 expressed in Chinese hamster ovary cells.

Authors:  B H Choi; J S Choi; S W Jeong; S J Hahn; S H Yoon; Y H Jo; M S Kim
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

6.  Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.

Authors:  Karsten Knobloch; Joachim Brendel; Stefan Peukert; Björn Rosenstein; Andreas E Busch; Klaus J Wirth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-05       Impact factor: 3.000

Review 7.  Epidemiology and natural history of atrial fibrillation: clinical implications.

Authors:  S S Chugh; J L Blackshear; W K Shen; S C Hammill; B J Gersh
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

Review 8.  Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation.

Authors:  Antoine Bril
Journal:  Curr Opin Pharmacol       Date:  2002-04       Impact factor: 5.547

9.  Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5).

Authors:  Ricardo Caballero; Ignacio Moreno; Teresa González; Carmen Valenzuela; Juan Tamargo; Eva Delpón
Journal:  Cardiovasc Res       Date:  2002-10       Impact factor: 10.787

10.  Papaverine blocks hKv1.5 channel current and human atrial ultrarapid delayed rectifier K+ currents.

Authors:  Han Choe; Yu-Kyung Lee; Yong-Tae Lee; Huhn Choe; Seong-Hoon Ko; Chan-Uhng Joo; Min-Ho Kim; Gong-Soo Kim; Jae-Soon Eun; Jong-Hyun Kim; Soo-Wan Chae; Yong-Geun Kwak
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

View more
  10 in total

1.  Putative binding sites for arachidonic acid on the human cardiac Kv 1.5 channel.

Authors:  Jia-Yu Bai; Wei-Guang Ding; Akiko Kojima; Tomoyoshi Seto; Hiroshi Matsuura
Journal:  Br J Pharmacol       Date:  2015-10-22       Impact factor: 8.739

2.  Regulation of human cardiac Kv1.5 channels by extracellular acidification.

Authors:  Shuang Wang; Wei-Guang Ding; Jia-Yu Bai; Futoshi Toyoda; Min-Jie Wei; Hiroshi Matsuura
Journal:  Pflugers Arch       Date:  2016-10-28       Impact factor: 3.657

Review 3.  Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.

Authors:  Lisa M Ballou; Richard Z Lin; Ira S Cohen
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

4.  Open channel block of Kv1.5 currents by citalopram.

Authors:  Hyang Mi Lee; Sang June Hahn; Bok Hee Choi
Journal:  Acta Pharmacol Sin       Date:  2010-03-15       Impact factor: 6.150

5.  Insulin suppresses IKs (KCNQ1/KCNE1) currents, which require β-subunit KCNE1.

Authors:  Minghua Wu; Yutaro Obara; Ikuo Norota; Yoshinobu Nagasawa; Kuniaki Ishii
Journal:  Pflugers Arch       Date:  2013-09-26       Impact factor: 3.657

6.  Rational Design and Synthesis of 3-Morpholine Linked Aromatic-Imino-1H-Indoles as Novel Kv1.5 Channel Inhibitors Sharing Vasodilation Effects.

Authors:  Wei Qin; Yi-Heng Li; Jing Tong; Jie Wu; Dong Zhao; Hui-Jin Li; Lu Xing; Chun-Xia He; Xin Zhou; Peng-Quan Li; Ge Meng; Shao-Ping Wu; Hui-Ling Cao
Journal:  Front Mol Biosci       Date:  2022-01-24

7.  Open channel block of Kv1.5 channels by HMQ1611.

Authors:  Chao Dong; Jiawei Li; Weiguang Ding; Rika Ueda; Xiaolu Xie; Jie Wu; Hiroshi Matsuura; Minoru Horie
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

8.  Improved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatment.

Authors:  Wei-Guang Ding; Yu Xie; Futoshi Toyoda; Hiroshi Matsuura
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

9.  Blockade of Kv1.5 channels by the antidepressant drug sertraline.

Authors:  Hyang Mi Lee; Sang June Hahn; Bok Hee Choi
Journal:  Korean J Physiol Pharmacol       Date:  2016-02-23       Impact factor: 2.016

Review 10.  Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5.

Authors:  Zefeng Zhao; Songsong Ruan; Xiaoming Ma; Qian Feng; Zhuosong Xie; Zhuang Nie; Peinan Fan; Mingcheng Qian; Xirui He; Shaoping Wu; Yongmin Zhang; Xiaohui Zheng
Journal:  Biomolecules       Date:  2019-12-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.